JPRN-jRCT1090220182已完成Unknown
Prospective observational study of SGLT2 inhibitor, ipragliflozin in patients with type 2 diabetes - Prospective observational study of SGLT2 inhibitor, ipragliflozin in patients with type 2 diabetes
General Incorporated Association Nagoya Medical Association0 个研究点目标入组 600 人开始时间: 2014年6月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
A supplementary administration of a ipragliflozin not only improved HbA1c but also showed weight loss, decreased blood pressure, improved liver function, and the higher HbA1c at initiation and ALT at onset, the lower HbA1c after administration of ipragliflozin It was also suggested that patients' effect prevention awareness is expected to be improved by using a patient questionnaire with a amount, suggesting that there is a possibility of suppressing the occurrence rate of side effects of ipragliflozin . From these observations, we believe that additional administration of a ipragliflozin can be a useful choice in the treatment of type 2 diabetes.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •*Patients with type 2 diabetes
- •*Age 20 years or older, but 75 or younger
- •*Patients with insufficiently controlled diabetes who are continuing diet therapy and/or exercise therapy or drug therapy
- •*HbA1c 6.0% or more, but less than 9.5%
- •*Ability to give written informed consent
排除标准
- •*Patients with type 1 diabetes
- •*History of metabolic acidosis, severe ketosis, diabetic coma or total coma within 6 months
- •*Patients with severe infectious disease ,before or after surgery, or sever trauma
- •*Patients with moderate or severe renal dysfunction (serum creatinine level 1.5 mg/dL and more for male, 1.3 mg/dL and more for female)
- •*Occurrence of stroke, myocardial infarction or vascular complication required hospitalization within 6 months
- •*Under treatment with SGLT-2 inhibitors
- •*Pregnant, women on lactation or possibly pregnant women, or plan to pregnant during the study
- •*History of hypersensitivity to SGLT-2 inhibitors
- •*Ineligible patients according to the investigator's judgment
研究者
相似试验
已完成
不适用
A study of safety and efficacy of ipragliflozin in the treatment of diabetes in KanagawaJPRN-UMIN000014425The Study Group of the Diabetes Committee, Kanagawa Physicians Association500
已完成
4 期
Mechanisms of Weight Loss With SGLT2 InhibitionOverweightObesityType 2 DiabetesNCT02360774Beth Israel Deaconess Medical Center30
已完成
不适用
Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.Type 2 diabetes mellitusJPRN-UMIN000019098Graduate School of Medicine, University of the Ryukyus12
招募中
2 期
SGLT2 Inhibition with Empagliflozin on Metabolic, Cardiac and Renal Outcomes in Recent Cardiac Transplant RecipientsCardiac transplantRenal diseaseCardiovascular - Other cardiovascular diseasesMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseDiabetesACTRN12622000978763Garvan Institute of Medical Research100
已完成
2 期
Empagliflozin and Renal Oxygenation in Healthy VolunteersNephropathyNCT03093103Centre Hospitalier Universitaire Vaudois45